Hepion Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Apr 8, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 8, 2025
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| Year Ended December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(13,192,420) | $(48,926,042) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 791,645 | 1,340,311 |
| Depreciation | 30,758 | 67,131 |
| Amortization of debt discount | 1,268,817 | — |
| Inducement expense | 2,567,044 | — |
| Write-off related party note receivable | 600,000 | — |
| Change in fair value of derivative instrument-warrants | (5,579,263) | 1,317,646 |
| Change in fair value of contingent consideration | (2,020,000) | (440,000) |
| Change in deferred tax liability | — | (409,022) |
| Impairment of in-process research and development | — | 3,190,000 |
| Changes in operating assets and liabilities: | ||
| Accounts payable and accrued expenses | (4,545,565) | 302,919 |
| Right of use asset | 212,878 | 89,825 |
| Operating lease liability | (209,020) | (96,712) |
| Prepaid expenses and other assets | 1,858,823 | 2,675,066 |
| Net cash used in operating activities | (18,216,303) | (40,888,878) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | — | (14,304) |
| Investment in related party receivable | (600,000) | — |
| Net cash used in investing activities | (600,000) | (14,304) |
| Cash flows from financing activities: | ||
| Proceeds from the issuance of common stock and warrants, net of issuance costs | — | 4,494,950 |
| Proceeds from exercise of warrants, net | 1,849,707 | — |
| Proceeds from equity and debt issuance under SPA, net of discount | 2,500,000 | — |
| Net cash (used in) provided by financing activities | 4,349,707 | 4,494,950 |
| Effect of exchange rates on cash | 87,124 | 5,024 |
| Net decrease in cash | (14,379,472) | (36,403,208) |
| Cash at beginning of period | 14,785,880 | 51,189,088 |
| Cash at end of period | $406,408 | $14,785,880 |
| Supplementary disclosure of cash flow information: | ||
| Cash paid for interest | $— | $— |
| Supplementary disclosure of non-cash financing activities: | ||
| Conversion of Series C convertible preferred stock | $— | $1,000 |
| Inducement expense for issuance of Series B-1 and B-2 warrants | 2,821,399 | — |
| Stock-based liability awards reversed to additional paid-in capital | — | 2,983,006 |
| Operating lease asset additions | — | 252,118 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.